Avaliação dos marcadores sorológicos sIL 2R e CA 125 como indicadores prognósticos de linfoma cutâneo e linfoma multicêntrico em cães
Carregando...
Data
2018-02-26
Autores
Canavari, Isabela Cristina
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Estadual Paulista (Unesp)
Resumo
A expectativa de vida dos cães está aumentando e com isso, o diagnóstico de diferentes neoplasias, particularmente os linfomas, um dos tipos tumorais mais prevalentes. O prognóstico desses pacientes tem se pautado nas avaliações clínicas, laboratoriais e de imagem, as quais podem não indicar a presença da doença em início de curso. Com este estudo, objetivou-se avaliar a eficácia de marcadores sorológicos para melhor estabelecer o prognóstico de cães com linfoma cutâneo e multicêntrico. Foram realizadas dosagens do receptor solúvel de Interleucina 2 (sIL 2R) no soro de 9 cães sadios (grupo 1), 20 cães com linfoma cutâneo (grupo 2) e 9 cães com linfoma multicêntrico (grupo 3), e do Antígeno do câncer 125 (CA 125) em 14 cães sadios (grupo 4), 13 cães com linfoma cutâneo (grupo 5) e 11 cães com linfoma multicêntrico (grupo 6). Adicionalmente foram avaliados os tempos de sobrevida, os resultados de exames hematológicos e de imagem dos pacientes, os quais foram relacionados com as concentrações séricas dos marcadores sorológicos. Os resultados mostraram que não houve diferença estatística (p > 0,05) entre as dosagens dos marcadores sIL 2R nos grupos 1, 2 e 3 e de CA 125 entre os grupos 4, 5 e 6. Houve diferença (p < 0,05) entre os grupos 2 e 5 (linfoma cutâneo) e 3 e 6 (linfoma multicêntrico) em relação ao tempo de sobrevida, o qual foi menor nos animais diagnosticados com linfoma cutâneo. Em relação às contagens hematológicas, apenas o linfócitos diferiram entre os grupos 2 e 3 (p = 0,0265) e 5 e 6 (p = 0,0356). Os resultados desse estudo mostraram que as concentrações dos marcadores sorológicos sIL 2R e CA 125 não diferiram entre cães saudáveis e os diagnosticados com linfoma cutâneo ou multicêntrico, não evidenciando o potencial valor prognóstico nos casos de cães com linfoma.
The life expectancy of dogs is increasing and with that the diagnosis of different neoplasms, particularly the lymphomas, one of the more prevalent tumor types. The prognosis of these patients has been based on clinical, laboratory and imaging evaluations, which may not indicate the diagnosis at the initial stages of the disease. The aim of this study was to evaluate the efficacy of serological markers to better predict the prognosis of dogs with cutaneous and multicentric lymphoma. Serum level of the soluble Interleukin 2 receptor (sIL 2R) were performed in 9 healthy dogs (group 1), 20 dogs with cutaneous lymphoma (group 2) and 9 dogs with multicentric lymphoma (group 3), and the cancer antigen 125 (CA 125) in 14 healthy dogs (group 4), 13 dogs with cutaneous lymphoma (group 5) and 11 dogs with multicentric lymphoma (group 6). In addition, survival times, hematological tests and imaging exams of oncological patients were performed to better evaluate the aggressiveness of the neoplasms and to correlate these results with the dosed serum markers. The results showed that there was no statistical difference (p > 0.05) in the dosages of sIL 2R between groups 1, 2 and 3 and CA 125 between groups 4, 5 and 6. There was difference (p < 0,05) between the groups 2 and 5 (cutaneous lymphoma) and 3 and 6 (multicentric lymphoma) in relation to the survival time, which was lower in the animals diagnosed with cutaneous lymphoma. In relation to hematological counts, only lymphocytes counts differed between the groups 2 and 3 (p = 0,0265) and 5 and 6 (p = 0,0356). The results of this study showed that sIL 2R and CA 125 concentrations did not differ between healthy dogs and those diagnosed with cutaneous or multicentric lymphoma, not evidencing their potential prognostic value in the cases of dogs with lymphoma.
The life expectancy of dogs is increasing and with that the diagnosis of different neoplasms, particularly the lymphomas, one of the more prevalent tumor types. The prognosis of these patients has been based on clinical, laboratory and imaging evaluations, which may not indicate the diagnosis at the initial stages of the disease. The aim of this study was to evaluate the efficacy of serological markers to better predict the prognosis of dogs with cutaneous and multicentric lymphoma. Serum level of the soluble Interleukin 2 receptor (sIL 2R) were performed in 9 healthy dogs (group 1), 20 dogs with cutaneous lymphoma (group 2) and 9 dogs with multicentric lymphoma (group 3), and the cancer antigen 125 (CA 125) in 14 healthy dogs (group 4), 13 dogs with cutaneous lymphoma (group 5) and 11 dogs with multicentric lymphoma (group 6). In addition, survival times, hematological tests and imaging exams of oncological patients were performed to better evaluate the aggressiveness of the neoplasms and to correlate these results with the dosed serum markers. The results showed that there was no statistical difference (p > 0.05) in the dosages of sIL 2R between groups 1, 2 and 3 and CA 125 between groups 4, 5 and 6. There was difference (p < 0,05) between the groups 2 and 5 (cutaneous lymphoma) and 3 and 6 (multicentric lymphoma) in relation to the survival time, which was lower in the animals diagnosed with cutaneous lymphoma. In relation to hematological counts, only lymphocytes counts differed between the groups 2 and 3 (p = 0,0265) and 5 and 6 (p = 0,0356). The results of this study showed that sIL 2R and CA 125 concentrations did not differ between healthy dogs and those diagnosed with cutaneous or multicentric lymphoma, not evidencing their potential prognostic value in the cases of dogs with lymphoma.
Descrição
Palavras-chave
Cães, Linfoma, Biomarcadores, Prognóstico, Lymphoma, Biomarkers, Prognosis, Dogs